Presentation at the IVRA 2025 International Medical Conference

Effectiveness is enhanced when combined with existing treatments

"Academic research is needed for clinical evidence"

▲Professor Jang Hong-seok of Seoul St. Mary's Hospital presents a case of hyperthermia treatment for a terminally ill patient. Photo by Park Hyo-sun.

 

"Hyperthermia cancer therapy is emerging as an effective combination treatment for cancer, thanks to recent technological advancements that allow for the stable delivery of desired temperatures. Theoretically, hyperthermia therapy has minimal side effects and enhances immunity, making it a promising option for combined use."

At the 8th IVRA 2025 International Medical Conference held at Seoul St. Mary's Hospital of the Catholic University of Korea on the 22nd, Professor Kim Eui-shin (MD Anderson Professor), a world-renowned authority on cancer treatment, said, "Cancer is difficult to treat due to its complex mechanisms, and therefore I have to be cautious if I want to mention a complete cure."

Professor Kim diagnosed, “Recently, immunotherapy, along with hormone and targeted therapy, has been attracting attention as an alternative, but these too have limitations.” He added, “When new technologies are introduced, there are many cases where existing medical professionals misunderstand that diagnosis and treatment are threatened,” and emphasized, “In Korea, in particular, the structure makes it difficult to connect departments, but patient-centered integrative medicine must be the future direction of cancer treatment.”

Professor Jang Hong-seok of Seoul St. Mary's Hospital said, "I feel regretful that there are difficulties in organizing data to establish a basis for effective hyperthermia cancer treatment, which is mainly used in nursing hospitals," adding, "We will further strengthen the clinical basis for terminal cancer patients."

On this day, AdipoLABs CEO Han Sung-ho said, “The biggest disease facing humanity after COVID-19 is cancer,” and added, “We will continue to create opportunities for communication on new approaches and treatments for cancer, including immunity and pain.” He added, “We plan to hold conferences twice a year in Korea in the spring and in Southeast Asia in the fall and winter, and we are also preparing events in China, the Philippines, and other countries.”

The high-frequency hyperthermia cancer treatment device, REMISSION 1℃, manufactured by this company, was approved by the Ministry of Food and Drug Safety for cancer treatment purposes in October 2015, and is a domestically produced medical device that has obtained European CE certification, Halal certification, and Malaysian MDA certification.

The main speakers at this conference included Professor Kang Young-nam (Department of Radiation Oncology, Seoul St. Mary's Hospital), Professor Hyun Myeong (Ilsan Cha Hospital), Director Lee Chan-yong (Seoul Oncare), Director Shin Hyeong-jin (EM365 Clinic), Director Yang Jae-ho (Jongno Chihu Oriental Medicine Hospital), Director Ryu Jeong-man (Cheongju Nabisol Oriental Medicine Hospital), and Director Kim Jeong-hoon (Daegu Happy H Hospital).

Former Seoul St. Mary's Hospital President Kim Seung-jo and former Konkuk University Hospital President Jang Sang-geun chaired the session. Experts from around the world, including India, Malaysia, Australia, China, and Singapore, shared their latest treatment cases, earning recognition for their high academic value.